Trinity Biotech (TRIB) Competitors

Nymox Pharmaceutical (NASDAQ:NYMX) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.

Which has better valuation and earnings, NYMX or TRIB?

Nymox Pharmaceutical has higher earnings, but lower revenue than Trinity Biotech. Nymox Pharmaceutical is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nymox Pharmaceutical	N/A	N/A	-$6.58 million	-$0.04	-9.98
Trinity Biotech	$74.78 million	0.53	-$41.01 million	-$1.29	-0.81

Do insiders & institutionals hold more shares of NYMX or TRIB?

0.8% of Nymox Pharmaceutical shares are held by institutional investors. Comparatively, 18.4% of Trinity Biotech shares are held by institutional investors. 54.0% of Nymox Pharmaceutical shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor NYMX or TRIB?

Trinity Biotech received 127 more outperform votes than Nymox Pharmaceutical when rated by MarketBeat users. Likewise, 68.06% of users gave Trinity Biotech an outperform vote while only 51.55% of users gave Nymox Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Nymox Pharmaceutical	Outperform Votes 150 51.55%	Underperform Votes 141 48.45%
Trinity Biotech	Outperform Votes 277 68.06%	Underperform Votes 130 31.94%

Is NYMX or TRIB more profitable?

Nymox Pharmaceutical has a net margin of 0.00% compared to Trinity Biotech's net margin of -54.84%. Trinity Biotech's return on equity of -724.07% beat Nymox Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nymox Pharmaceutical	N/A	-1,589.50%	-117.25%
Trinity Biotech	-54.84%	-724.07%	-25.12%

Do analysts rate NYMX or TRIB?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nymox Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Trinity Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has more risk and volatility, NYMX or TRIB?

Nymox Pharmaceutical has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Does the media refer more to NYMX or TRIB?

In the previous week, Trinity Biotech had 3 more articles in the media than Nymox Pharmaceutical. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for Nymox Pharmaceutical. Trinity Biotech's average media sentiment score of 0.43 beat Nymox Pharmaceutical's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Nymox Pharmaceutical	Neutral
Trinity Biotech	Neutral

Summary

Trinity Biotech beats Nymox Pharmaceutical on 10 of the 14 factors compared between the two stocks.